CAJ | 학술논문

目的：探讨分析支气管动脉灌注化疗结合静脉化疗治疗中晚期非小细胞型肺癌的临床疗效。方法：2009年2月-2013年2月收治中晚期非小细胞肺癌患者35例，第1天经支气管动脉灌注健择(进口盐酸吉西他滨)、顺铂，第8、15天予健择全身静脉化疗，28天1个周期，所有患者至少接受2个周期治疗，2个周期后评价疗效及不良反应。结果：所有患者中完全缓解3例，部分缓解22例，稳定8例，进展2例，总有效率71.4%；半年生存率100%，1年生存率54.3%；患者均出现了不同程度的不良反应。结论：支气管动脉灌注结合静脉化疗序贯治疗中晚期非小细胞型肺癌，疗效较好，不良反应可耐受，具有较高的临床应用价值。
목적：탐토분석지기관동맥관주화료결합정맥화료치료중만기비소세포형폐암적림상료효。방법：2009년2월-2013년2월수치중만기비소세포폐암환자35례，제1천경지기관동맥관주건택(진구염산길서타빈)、순박，제8、15천여건택전신정맥화료，28천1개주기，소유환자지소접수2개주기치료，2개주기후평개료효급불량반응。결과：소유환자중완전완해3례，부분완해22례，은정8례，진전2례，총유효솔71.4%；반년생존솔100%，1년생존솔54.3%；환자균출현료불동정도적불량반응。결론：지기관동맥관주결합정맥화료서관치료중만기비소세포형폐암，료효교호，불량반응가내수，구유교고적림상응용개치。
To explore and analyze the clinical effect of bronchial artery infusion combined with intravenous chemotherapy in the treatment of middle to late stage non-small cell lung cancer.Methods:35 cases with middle to late stage non-small cell lung cancer were selected from February 2009 to February 2013.They were given bronchial artery infusion gemzar(imported gemcitabine hydrochloride) and cisplatin at the first day.They were given intravenous chemotherapy gemzar.28 days were one cycle.All cases received at least 2 cycles of treatment,and the efficacy and adverse reactions were evaluated after 2 cycles.Results:In all cases,3 cases were complete remission;22 cases were partial remission;8 cases were stable;2 cases were progress.The total effective rate was 71.4%.The half year survival rate was 100%.The 1 year survival rate was 54.3%.The patients showed different degree of adverse reactions.Conclusion:Bronchial artery infusion combined with intravenous chemotherapy in the sequential treatment of middle to late stage non-small cell lung cancer has better curative effect.Its adverse reactions can be tolerated.It has high value in clinical application.